{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:04:02Z","timestamp":1758125042034},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","gastro.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.gtc.2015.07.010","type":"journal-article","created":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T21:22:30Z","timestamp":1439068950000},"page":"871-881","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Current Treatment Options in Patients with Hepatitis C Virus Genotype 6"],"prefix":"10.1016","volume":"44","author":[{"given":"Nghia H.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gtc.2015.07.010_bib1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/apt.12551","article-title":"Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6","volume":"39","author":"Wantuck","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gtc.2015.07.010_bib2","first-page":"35","article-title":"Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium","volume":"6","year":"1999","journal-title":"J\u00a0Viral Hepat"},{"issue":"10","key":"10.1016\/j.gtc.2015.07.010_bib3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/apt.12300","article-title":"Systematic review: Asian patients with chronic hepatitis C infection","volume":"37","author":"Nguyen","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.gtc.2015.07.010_bib4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cld.2005.05.010","article-title":"Chronic hepatitis C: genotypes 4 to 9","volume":"9","author":"Nguyen","year":"2005","journal-title":"Clin Liver Dis"},{"issue":"10 Suppl 2","key":"10.1016\/j.gtc.2015.07.010_bib5","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S1542-3565(05)00711-1","article-title":"Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6","volume":"3","author":"Nguyen","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2015.07.010_bib6","unstructured":"AASLD\/IDSA\/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. 2015. Available at: http:\/\/www.hcvguidelines.org\/fullreport. Accessed April 2, 2015."},{"issue":"3","key":"10.1016\/j.gtc.2015.07.010_bib7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2036.2011.04714.x","article-title":"Systematic review: epidemiology of hepatitis C genotype 6 and its management","volume":"34","author":"Chao","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gtc.2015.07.010_bib8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3350\/cmh.2013.19.1.45","article-title":"Clinical and epidemiological characteristics of Korean patients with hepatitis C virus genotype 6","volume":"19","author":"Seong","year":"2013","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.gtc.2015.07.010_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12072-010-9181-7","article-title":"Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans","volume":"4","author":"Nguyen","year":"2010","journal-title":"Hepatol Int"},{"issue":"10","key":"10.1016\/j.gtc.2015.07.010_bib10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2893.2009.01226.x","article-title":"Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2\/3 vs 6","volume":"17","author":"Nguyen","year":"2010","journal-title":"J\u00a0Viral Hepat"},{"issue":"5","key":"10.1016\/j.gtc.2015.07.010_bib11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/hep.23889","article-title":"Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6","volume":"52","author":"Lam","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.gtc.2015.07.010_bib12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jhep.2011.12.020","article-title":"A\u00a0randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C","volume":"56","author":"Thu Thuy","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gtc.2015.07.010_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s12072-014-9570-4","article-title":"Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks","volume":"8","author":"Nguyen","year":"2014","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gtc.2015.07.010_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2015.04.003","article-title":"Interferon-free therapy for hepatitis C: the hurdles amid a golden era","author":"Colombo","year":"2015","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.gtc.2015.07.010_bib15","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.gtc.2015.07.010_bib16","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJMp1400160","article-title":"Treating hepatitis C in lower-income countries","volume":"370","author":"Jayasekera","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.gtc.2015.07.010_bib17","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/j.gastro.2014.03.008","article-title":"Impact of new hepatitis C treatments in different regions of the world","volume":"146","author":"Wei","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.gtc.2015.07.010_bib18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.12998\/wjcc.v3.i3.210","article-title":"Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6","volume":"3","author":"Papastergiou","year":"2015","journal-title":"World J Clin Cases"},{"issue":"7","key":"10.1016\/j.gtc.2015.07.010_bib19","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/jvh.12047","article-title":"Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection","volume":"20","author":"Seto","year":"2013","journal-title":"J\u00a0viral Hepat"},{"issue":"5","key":"10.1016\/j.gtc.2015.07.010_bib20","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/ajg.2011.40","article-title":"The effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6","volume":"106","author":"Seto","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"7265","key":"10.1016\/j.gtc.2015.07.010_bib21","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"issue":"S1","key":"10.1016\/j.gtc.2015.07.010_bib22","first-page":"1855","article-title":"Shortened treatment duration in treatment-naive genotype 6 chronic hepatitis C patients with rapid virological response: a randomized controlled trial","volume":"58","author":"Cai Qing-Xian","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gtc.2015.07.010_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000369097","article-title":"Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirin","volume":"58","author":"Nguyen","year":"2015","journal-title":"Intervirology"},{"issue":"13","key":"10.1016\/j.gtc.2015.07.010_bib24","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.gtc.2015.07.010_bib25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10620-015-3621-0","article-title":"Poor sustained virological response in a multicenter real-life cohort of chronic hepatitis C patients treated with pegylated interferon and ribavirin plus telaprevir or boceprevir","volume":"60","author":"Vo","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.gtc.2015.07.010_bib26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"9883","key":"10.1016\/j.gtc.2015.07.010_bib27","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(13)60247-0","article-title":"Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial","volume":"381","author":"Kowdley","year":"2013","journal-title":"Lancet"},{"issue":"4 Supplement 1","key":"10.1016\/j.gtc.2015.07.010_bib28","doi-asserted-by":"crossref","first-page":"S-1088","DOI":"10.1016\/S0016-5085(15)33716-1","article-title":"Treatment response and tolerability of simeprevir (SMV)-based or sofosbuvir (SOF)-based therapy for the treatment of genotype 6 (HCV-6) chronic hepatitis C infection","volume":"148","author":"Vu","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gtc.2015.07.010_bib29","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/S0168-8278(14)60113-6","article-title":"Safety and efficacy of treatment with interferon-free, ribavirin-free combination of sofosbuvir\u00a0+ GS-5816 for 12 weeks in treatment-naive patients with genotypes 1-6 HCV infection","volume":"60","author":"Everson","year":"2014","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2015.07.010_bib30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jhep.2011.12.033","article-title":"Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study","volume":"56","author":"Moreno","year":"2012","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2015.07.010_bib31","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.gtc.2015.07.010_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.gtc.2015.07.010_bib33","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2015.3868","article-title":"Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis","volume":"313","author":"Muir","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.gtc.2015.07.010_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hep.27890","article-title":"Safety and tolerability of ledipasvir\/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection: analysis of phase 3 ION trials","volume":"62","author":"Alqahtani","year":"2015","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.gtc.2015.07.010_bib35","first-page":"LB-11","article-title":"High efficacy of LDV\/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection","volume":"60","author":"Gane","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.gtc.2015.07.010_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.gtc.2015.07.010_bib37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1517\/14656566.2015.1024653","article-title":"ABT-450\/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus","volume":"16","author":"Minaei","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.gtc.2015.07.010_bib38","first-page":"172","article-title":"Pharmaceutical approval update","volume":"40","author":"Gohil","year":"2015","journal-title":"P\u00a0T"},{"issue":"11","key":"10.1016\/j.gtc.2015.07.010_bib39","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1572-0241.2005.00282.x","article-title":"A\u00a0randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C","volume":"100","author":"Jacobson","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.gtc.2015.07.010_bib40","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2015.07.010_bib41","doi-asserted-by":"crossref","DOI":"10.3851\/IMP2964","article-title":"Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype 1-infected individuals","author":"Nguyen","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.gtc.2015.07.010_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","article-title":"Update on hepatitis C virus resistance to direct-acting antiviral agents","volume":"108","author":"Poveda","year":"2014","journal-title":"Antivir Res"},{"issue":"1","key":"10.1016\/j.gtc.2015.07.010_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hep.27836","article-title":"Sofosbuvir plus peginterferon and ribavirin in patients with genotype 1 HCV in whom prior therapy with direct-acting antivirals has failed","volume":"62","author":"Pol","year":"2015","journal-title":"Hepatology"},{"issue":"24","key":"10.1016\/j.gtc.2015.07.010_bib44","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.gtc.2015.07.010_bib45","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.cgh.2011.05.028","article-title":"Effects of a sustained virologic response on outcomes of patients with chronic hepatitis C","volume":"9","author":"Ng","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2015.07.010_bib46","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1572-0241.2008.01793.x","article-title":"Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.gtc.2015.07.010_bib47","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.clinthera.2015.02.009","article-title":"Finding truth in a world full of spin: myth-busting in the case of Sovaldi","volume":"37","author":"Schiff","year":"2015","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.gtc.2015.07.010_bib48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/cid\/civ220","article-title":"The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus","volume":"61","author":"Rein","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855315000771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855315000771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T05:23:25Z","timestamp":1537421005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855315000771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0889855315000771"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2015.07.010","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Treatment Options in Patients with Hepatitis C Virus Genotype 6","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2015.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}